Retour au classement

Elevance Health Inc (ELV)

Juste valeur
HealthcareHealthcare PlansUnited States

Fondamental

71

Prix

$388.82

Capitalisation boursière

$85.57B

Partie 1 · Ce que vaut l'entreprise

Vue d'ensemble

Elevance Health, Inc., together with its subsidiaries, operates as a health benefits company in the United States. The company operates in four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to individual, employer group risk-based and fee-based, BlueCard, Medicare, Medicaid, and FEP members; health products; a broad array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, and supplemental health insurance benefits. The company also operates in the pharmacy services business; and markets and offers pharmacy services, including home delivery and specialty pharmacies, claims adjudication, formulary management, pharmacy networks, rebate administration, a prescription drug database, and member services, as well as infusion services and injectable therapies through ambulatory infusion centers. In addition, it provides healthcare related services and capabilities, including specialty care enablement and utilization management support for specialized clinical domains; behavioral health and comprehensive care management services; palliative care services and management; virtual care; and payment integrity, subrogation, clinical data exchange through its HealthOS platform, research and data, reporting and clinical analytics, information technology, and business process support services, as well as manages home health, post-acute institutional management, and durable medical equipment costs; and supports plans in managing home and community-based services. The company provides its services under the Anthem Blue Cross and Blue Shield, Wellpoint, and Carelon brands. The company was formerly known as Anthem, Inc. and changed its name to Elevance Health, Inc. in June 2022. Elevance Health, Inc. was incorporated in 2001 and is based in Indianapolis, Indiana.

No editorial profile for this company yet

Direct competitors

Who this company fights with for the same customers

Compare

Generated on 18 septembre 2026 with claude-haiku-4-5 — shared with all users

P/E: 23.6Score: 80Market cap: $336.61B

The largest US health insurer, bidding against Elevance for the same employer contracts, Medicare Advantage members and state Medicaid programs, and pairing insurance with health services just as Elevance does with Carelon.

P/E: 22.6Score: 64Market cap: $112.36B

Through Aetna it sells commercial, Medicare Advantage and Medicaid plans in the same states as Elevance, and its pharmacy benefit arm competes for the same drug-benefit spending.

P/E: —Score: 59Market cap: $30.89B

The biggest Medicaid managed-care company in the country and Elevance's main rival in state Medicaid procurements and on the Affordable Care Act exchanges.

P/E: 11.2Score: 73Market cap: $71.83B

Competes head-on for large national and multi-state employer accounts, the segment where Elevance's Blue Cross Blue Shield network is its main selling point.

P/E: 40.7Score: 67Market cap: $46.78B

Concentrated on Medicare Advantage, where it competes for the same over-65 members Elevance is courting as its fastest-growing business.

Molina Healthcare, Inc.MOH

A pure-play government-programs insurer that bids against Elevance for the same state Medicaid and dual-eligible contracts.

Bilan & Liquidités

Chiffre d'affaires

$199.13B

Exercice clos le 31/12/2025

Résultat net

$5.66B

Exercice clos le 31/12/2025

Flux de trésorerie libre

$3.17B

Capitaux propres totaux

$43.88B

Passif total

$77.47B

Ratio de liquidité général

1.52

Couverture des intérêts

5.13

Dette/EBITDA

3.55

Bénéfice par action

Chiffre d'affaires & Résultat net

Flux de trésorerie libre

Décomposition du résultat

État historique

Marges dans le temps

La dette dans le temps

Le poids de la dette

Grille de la croissance

Croissance — Chiffre d'affaires

Estimation de la juste valeur

Cas généralJustement valorisé

Juste valeur

$497.22

Prix actuel

$388.82

Marge de sécurité

+21.8%

Fourchette de juste valeur

$323.19 - $671.25

Écart entre les méthodes de valorisation utilisées, pas un intervalle de confiance calibré statistiquement.

Méthodes d'estimation

Objectif de cours des analystes:$451.38
Flux de trésorerie actualisés (DCF):$1058.45
Multiple de résultat (P/E):$315.56
Formule de croissance de Graham:$447.48
Valeur de la capacité bénéficiaire (EPV):$327.00
P/B justifié:$351.57
Actualisation des dividendes (Gordon):$173.31
P/FFO, les fonds provenant de l'exploitation:$531.79
Bénéfices de milieu de cycle:$1031.71
Multiple sur le chiffre d'affaires:$3636.37
Consensus des analystes:Acheter (19B / 10H / 0S)
Dernière surprise sur les résultats:+18.85%

Indicateurs de valorisation

Ratio P/E

15.65

ROE

12.9%

Ratio P/B

1.88

P/FCF

13.41

Marge brute

89.4%

ROIC

7.1%

Radar de rentabilité

Création de valeur (avantage concurrentiel)

ROIC

7.1%

WACC

6.9%

ROIC − WACC

+0.2 pp

Le ROIC est à peu près aligné sur le coût du capital — l'entreprise couvre à peine son coût du capital.

Critères d'analyse fondamentale

Réussi (21)

  • EPS shows upward trend
  • EPS CAGR 8.76%
  • Price CAGR 11.28%
  • ROIC 7.1%
  • Gross Margin 89.4%
  • P/FCF 13.41
  • P/B Ratio 1.88
  • Debt/Equity ratio
  • Positive Free Cash Flow
  • CapEx intensity
  • Current Ratio
  • Interest Coverage
  • Debt/EBITDA
  • Return on Tangible Assets
  • ROE 11.2%
  • Revenue Growth 5Y 10.3%
  • Analyst Consensus 66% Buy
  • Earnings Surprise avg 15.4%
  • Earnings Quality (OCF/NI) 0.76
  • Share Dilution -3.6%
  • Piotroski F-Score 7/9

Échoué (5)

  • Operating Margin 3.6%
  • Low reliance on intangibles
  • Price below Graham Number
  • DCF valuation (Overvalued)
  • PEG Ratio 2.47

Indisponible (2)

  • Dividend Payout NaN%
  • Net Margin Trend (invalid data)

Score F de Piotroski

7/9

Santé financière solide

score
criteria

Qualité des bénéfices

0.76

Modérée : certain écart entre profits et trésorerie

Dilution du capital

-3.6%

Rachat d'actions. Favorable aux actionnaires

Participations institutionnelles

Gouvernance

Équipe dirigeante

NomTitreÂge
Ms. Gail Koziara BoudreauxPresident, CEO & Director64
Mr. Mark Bradley KayeExecutive VP & CFO45
Mr. Peter David Haytaian Esq.Special Advisor55
Mr. Charles Morgan Kendrick Jr.EVP and President of Commercial & Specialty Health Benefits59
Ms. Felicia Farr NorwoodExecutive VP & Chief Health Benefits Officer65
Mr. Scott Wayne AnglinSVP, Treasurer & Chief Investment Officer-
Mr. Ronald William PenczekSenior VP, Controller & Chief Accounting Officer60
Mr. Nathan Allen RichVice President of Investor Relations-
Ms. Erin M. WesslingExecutive VP & Chief Legal Officer47
Ms. Julie GoonSenior Vice President of Public Affairs-

Risque d'audit

1

Risque du conseil

1

Risque de rémunération

2

Risque droits des actionnaires

6

Partie 2 · Le prix et le moment d'entrer

Cette partie ne dit pas si l'entreprise vaut la peine : elle aide à choisir quand l'acheter, une fois que les fondamentaux vous ont convaincu. À l'intérieur : analyse technique, potentiel, baisses historiques, exposition gamma.

Documents

  • Rapport annuel (10-K)

    Un aperçu annuel de l'activité, des résultats financiers et des risques de l'entreprise.

    Déposé le 2026-02-06

    Voir le document
  • Rapport trimestriel (10-Q)

    Une mise à jour de la performance financière des trois derniers mois.

    Déposé le 2026-07-15

    Voir le document
  • Rapport d'événement important (8-K)

    Un avis concernant un événement important, comme un changement de direction ou une annonce majeure.

    Déposé le 2026-09-10

    Voir le document

via SEC EDGAR

Historique des résultats

via SEC EDGAR

Latest News

Recent headlines for ELV, sourced from Markets Gazette.

  • 4/22/2026POSITIVE
    Elevance Health Earnings And Guidance Hike Offset Cost Concerns

    Elevance Health exceeded first-quarter earnings expectations, reporting $6.05 per share against a consensus of $5.70, a 6.1% beat. The company also raised its full-year 2026 outlook, projecting adjusted earnings per share between $18.40 and $18.80, up from the previous guidance of $18.20 to $18.60. This upward revision, coupled with steady revenue growth, suggests strong operational performance. However, investors should note the company flagged increased cost pressures in its Medicaid business and a significant accrual related to CMS rates, which could impact future profitability.

  • 4/7/2026POSITIVE
    Elevance Health Stock Soars After 2.48% Medicare Rate Increase

    Elevance Health Inc. experienced a significant surge on Tuesday following the finalization of a substantial 2.48% increase in Medicare Advantage reimbursement rates for 2027 by federal regulators. This favorable adjustment is expected to directly boost the company's revenue streams from its government-backed health insurance plans. For investors, this news signals improved profitability prospects and a more robust financial outlook for Elevance Health, potentially leading to upward price target revisions and increased institutional interest.

  • 3/2/2026NEGATIVE
    Elevance Health Stock Sinks After CMS Freezes Medicare Advantage Enrollment

    Markets Gazette reports a significant decline in Elevance Health's stock value following the Centers for Medicare & Medicaid Services (CMS) decision to freeze new enrollments in its Medicare Advantage program. The CMS action stems from serious compliance concerns dating back to 2018. This halt in new admissions represents a substantial blow to Elevance Health, as the Medicare Advantage program is a critical component of its business and future growth strategy. Investors reacted sharply, driving the stock price down, reflecting uncertainty about the long-term financial impact of these restrictions and the company's reputation. The situation demands careful management from the company's leadership to restore regulatory and market confidence.

  • 2/25/2026POSITIVE
    After stints at Nike and Kohl’s, Elevance Health’s CDIO pivots to using tech to bring more ‘delight’ to healthcare

    Ratnakar Lavu, with significant experience at retail giants like Nike and Kohl's, is taking on the role of Chief Digital and Information Officer (CDIO) at Elevance Health. This strategic move suggests a growing emphasis on technological innovation within the healthcare sector. Lavu's goal is to infuse healthcare with the same "delight" and customer-centric approach typical of retail, leveraging technology to enhance the overall patient and user experience. For investors, the arrival of an executive with such a diverse and consumer-oriented background could signal a potential acceleration in Elevance Health's digital transformation, promising greater operational efficiency and improved customer loyalty, key drivers for future growth.

  • 2/24/2026NEUTRAL
    Elevance Health Executive: Committed to Affordability

    Catherine Gaffigan, president of health solutions at Elevance Health, highlighted utilization as a key driver of rising healthcare costs. Speaking on Bloomberg's The Close, she elaborated that an aging population, coupled with higher pharmaceutical and hospital expenses, significantly contributes to this trend. These insights provide investors with an internal perspective on the structural challenges facing the healthcare sector. While Elevance Health is committed to affordability, the discussion around cost drivers underscores the complexity of the current landscape and the long-term pressures on healthcare providers and insurers. For investors, understanding these factors is crucial for assessing the sustainability of business models within the industry.

via Markets Gazette